Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
New Research - Salipro® enabled to unveil Taurine Transporter Secrets & Anti-Aging Potential
2025-04-03
Energy Drink Ingredient, Anti-Aging Clues & Advanced Structural Biology: How Salipro® Tech Helped Unlock Taurine Transporter Secrets!
You know taurine from energy drinks like Red Bull, but its real power lies deep within our cells, playing vital roles in health and even influencing the aging process. Understanding how taurine enters cells via the Taurine Transporter (TauT) is crucial, but studying this membrane protein presents significant technical challenges.
We're excited to share a new publication where the Salipro® platform was instrumental in overcoming these hurdles to reveal TauT's structure and function in unprecedented detail.
Congratulations to the authors on this impressive research!
Explore the detailed findings: H. Zhang, et al., Structural basis of augmenting taurine uptake by the taurine transporter in alleviating cellular senescence. Cell Research (2025)
Salipro invited to present at the Tumor Model Summit Nordics
2025-04-01
Are you attending the Tumor Model Summit next week (April 9-10th) in Stockholm, Sweden?
Please join us on Wednesday, the 9th of April as our CSO, Robin Löving, will take the stage to present the Salipro® platform and highlight the exciting advancements in developing antibodies against wild-type CXCR4.
Be sure to say hi to our newest talent, Mia Abramsson who also will be there.
Find more information on the conference here: https://tumour-models-nordics.com/
Press Release: Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
2025-03-13
The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable and accelerate the development of novel therapeutics.
Stockholm, Sweden, March 13, 2025 – Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.